Candel Therapeutics, Inc. CADL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$8.86M+70.0% | -$29.5M-162% | -$11.27M-135% | -$4.8M-165% | $7.38M+152% | ||
| $149K-8.6% | $163K-18.5% | $200K0.0% | $200K-18.4% | $245K0.0% | ||
| $1.45M+12.6% | $1.29M+10.9% | $1.16M+10.8% | $1.05M+234% | $314K-74.8% | ||
| —— | —— | -$300K— | —— | —— | ||
| $1.7M+5,045% | $33K— | —— | $1.01M+98.4% | $507K+1,005% | ||
| -$3.86M-269% | $2.29M— | —— | —— | -$2.37M-535% | ||
| $1.26M— | —— | —— | $1.94M+1,260% | -$167K+55.7% | ||
| -$22K-149% | $44.5K0.0% | $44.5K0.0% | $44.5K0.0% | $44.5K— | ||
| -$108K-2.9% | -$105K+18.6% | -$129K+7.2% | -$139K-2.2% | -$136K-1.5% | ||
| -$18.04M-70.7% | -$10.57M-3.2% | -$10.24M-15.1% | -$8.89M-3.2% | -$8.62M-48.2% | ||
| $675K+65.0% | $409K+184% | $144K+365% | $31K+933% | $3K0.0% | ||
| —— | $6.75K0.0% | $6.75K0.0% | $6.75K0.0% | $6.75K— | ||
| -$675K-65.0% | -$409K-250% | -$117K-277% | -$31K-933% | -$3K0.0% | ||
| $28K— | —— | —— | $4.65M+1,112% | $384K— | ||
| $93.82M+114% | $43.9M— | $0-100% | $17.44M+1,033% | -$1.87M-102% | ||
| $75.1M+128% | $32.92M+340% | -$13.72M-261% | $8.52M+181% | -$10.49M-112% | ||
| $1.22M+72.4% | $709K+458% | $127K-33.9% | $192K-23.8% | $252K-24.3% | ||
| —— | —— | —— | —— | —— | ||
| $306K+16.3% | $263K+1,152% | $21K-34.4% | $32K-27.3% | $44K-15.4% | ||
| $149K-8.6% | $163K-18.5% | $200K0.0% | $200K-18.4% | $245K0.0% | ||
| -$108K-2.9% | -$105K+18.6% | -$129K+7.2% | -$139K-2.2% | -$136K-1.5% | ||
| $21K+950% | $2K-95.0% | $40K+408% | -$13K-160% | -$5K+58.3% | ||
| $1.26M— | —— | —— | $1.94M+1,260% | -$167K+55.7% | ||
| $39K+11.4% | $35K+2.9% | $34K-2.9% | $35K+2.9% | $34K+13.3% | ||
| $92K+3.4% | $89K+9.9% | $81K+5.2% | $77K+4.1% | $74K+2.8% | ||
| —— | $11.99M0.0% | $11.99M0.0% | $11.99M0.0% | $11.99M— | ||
| —— | -$4.23M-69.3% | -$2.5M0.0% | -$2.5M0.0% | -$2.5M0.0% | ||
| $39K+457% | $7K-93.8% | $112K— | $0-100% | $16K— | ||
| $299K— | —— | —— | —— | -$25K— | ||
| —— | $23.25K0.0% | $23.25K0.0% | $23.25K0.0% | $23.25K— | ||
| -$7.64M— | —— | -$1.15M+79.9% | -$5.69M+61.8% | -$14.88M-355% | ||
| -$22K-149% | $44.5K0.0% | $44.5K0.0% | $44.5K0.0% | $44.5K— | ||
| -$108K-2.9% | -$105K+18.6% | -$129K+7.2% | -$139K-2.2% | -$136K-1.5% | ||
| —— | $519.75K0.0% | $519.75K0.0% | $519.75K0.0% | $519.75K— | ||
| -$18.71M-70.5% | -$10.98M-5.8% | -$10.38M-16.3% | -$8.92M-3.5% | -$8.62M-48.2% | ||
| -$18.71M-70.5% | -$10.98M-5.8% | -$10.38M-16.3% | -$8.92M-3.5% | -$8.62M-48.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Candel Therapeutics, Inc. generate?
- Candel Therapeutics, Inc. (CADL) generated -$47.7M in operating cash flow over the trailing twelve months.
- What is Candel Therapeutics, Inc.'s free cash flow?
- After $1.3M of capital expenditures, Candel Therapeutics, Inc.'s free cash flow was -$49.0M over the trailing twelve months, down 80.0% year over year.
- Where does Candel Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
